Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D, Angelakopoulos C, Apalla Z, Georgiou S, Delli F, Drosos A, Zafiriou E, Katsantonis J, Lazaridou E, Panagakis P, Papadavid E, Papakonstantis M, Roussaki-Schulze AV, Sotiriou E, Anastasiadis G, Tampouratzi E, Chasapi V, Sfaelos K, Ioannides D; BrIDGE Study Group. Rigopoulos D, et al. Among authors: chasapi v. Dermatol Ther. 2022 Dec;35(12):e15886. doi: 10.1111/dth.15886. Epub 2022 Nov 1. Dermatol Ther. 2022. PMID: 36184757
Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population.
Rigopoulos D, Lazaridou E, Papadavid E, Georgiou S, Chasapi V, Sfaelos K, Cheliotis G, Ioannides D. Rigopoulos D, et al. Among authors: chasapi v. Dermatol Ther. 2022 Jun;35(6):e15484. doi: 10.1111/dth.15484. Epub 2022 May 9. Dermatol Ther. 2022. PMID: 35373423
Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Rigopoulos D, Tampouratzi E, Angelakopoulos C, Apalla Z, Barkis I, Georgiou S, Delli F, Drosos A, Zafiriou E, Katsantonis J, Lazaridou E, Panagakis P, Papadavid E, Papakonstantis M, Roussaki-Schulze AV, Sotiriou E, Anastasiadis G, Chasapi V, Sfaelos K, Ioannides D; BrIDGE Study Group. Rigopoulos D, et al. Among authors: chasapi v. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1121-1130. doi: 10.1111/jdv.19816. Epub 2024 Feb 3. J Eur Acad Dermatol Venereol. 2024. PMID: 38308561
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Rompoti N, Stefanaki I, Panagakis P, Papoutsaki M, Politou M, Vavouli C, Befon A, Kousta F, Lazou E, Zaimi M, Koumprentziotis IA, Chasapi V, Rigopoulos D, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: chasapi v. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e1-e4. doi: 10.1111/jdv.19956. Epub 2024 Mar 20. J Eur Acad Dermatol Venereol. 2025. PMID: 38506605 No abstract available.
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.
Rompoti N, Vergou T, Stefanaki I, Vavouli C, Koumprentziotis IA, Panagakis P, Papoutsaki M, Politou M, Befon A, Kousta F, Lazou E, Zaimi M, Chasapi V, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: chasapi v. Int J Dermatol. 2024 Oct;63(10):e255-e258. doi: 10.1111/ijd.17400. Epub 2024 Jul 25. Int J Dermatol. 2024. PMID: 39051109 No abstract available.
43 results